Literature DB >> 20233808

Impaired anti-platelet effect of aspirin, inflammation and platelet turnover in cardiac surgery.

Hernán Cohen Arazi1, David G Doiny, Ricardo Spampinato Torcivia, Hugo Grancelli, Silvina V Waldman, Carlos Nojek, María Cecilia Fornari, Juan Jose Badimon.   

Abstract

A reduced platelet inhibitory response to acetyl salicylic acid (ASA) has been associated with an increased risk of graft thrombotic occlusion after coronary artery bypass grafting (CABG). We performed a prospective, observational study of 18 patients on 100 mg/day ASA before and after CABG. We assessed antiplatelet response to ASA and its relationship with platelet turnover, inflammatory markers, and soluble thrombomodulin (sTM) levels. All patients showed optimal response to ASA preoperatively but had higher values during follow-up. Platelet aggregation and platelet count in the perioperative period were significantly associated (P=0.05). Platelet turnover was defined as the average daily turnover (ADTO). The lowest inhibitory value (28% of patients > or =6 Omega) was recorded at the same time of the highest platelet turnover (>10% daily in 77.77% of patients), one week after CABG. ADTO >10% was associated with an increased risk of platelet aggregation > or =6 Omega. Levels of sTM were significantly higher one week after CABG (median 13 vs. 3 ng/ml preoperatively, P=0.0011). There is a transient impairment in ASA antiplatelet effect after CABG related to an increased platelet turnover caused by the inflammatory process. This could be responsible for the high risk of occlusive thrombosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20233808     DOI: 10.1510/icvts.2009.229542

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  5 in total

1.  The Prevalence and Clinical Relevance of ASA Nonresponse After Cardiac Surgery: A Prospective Bicentric Study.

Authors:  Saskia Wand; Elisabeth Hannah Adam; Anna Julienne Wetz; Patrick Meybohm; Nils Kunze-Szikszay; Kai Zacharowski; Aron Frederick Popov; Anton Moritz; Lisa Moldenhauer; Julia Kaiser; Martin Bauer; Christian Friedrich Weber
Journal:  Clin Appl Thromb Hemost       Date:  2017-02-23       Impact factor: 2.389

Review 2.  Circulating Thrombomodulin: Release Mechanisms, Measurements, and Levels in Diseases and Medical Procedures.

Authors:  Mallorie Boron; Tiffany Hauzer-Martin; Joseph Keil; Xue-Long Sun
Journal:  TH Open       Date:  2022-07-11

3.  Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome.

Authors:  William A E Parker; Rachel C Orme; Jessica Hanson; Hannah M Stokes; Claire M Bridge; Patricia A Shaw; Wael Sumaya; Kirstie Thorneycroft; Giovanna Petrucci; Benedetta Porro; Heather M Judge; Ramzi A Ajjan; Bianca Rocca; Robert F Storey
Journal:  Platelets       Date:  2019-02-13       Impact factor: 3.862

Review 4.  Thrombomodulin and the vascular endothelium: insights into functional, regulatory, and therapeutic aspects.

Authors:  Fiona A Martin; Ronan P Murphy; Philip M Cummins
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-04-19       Impact factor: 4.733

5.  Perioperative urinary thromboxane metabolites and outcome of coronary artery bypass grafting: a nested case-control study.

Authors:  Hanning Liu; Zhengxi Xu; Zhou Zhou; Xiaoqi Wang; Zhe Zheng; Cheng Sun; Qianlong Chen; Ning Bao; Wen Chen
Journal:  BMJ Open       Date:  2018-08-30       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.